你知道吗？2025年3月11日，辉瑞公司在clinicaltrials网站上登记了CD25ADC药物PF-08046032的首个临床试验（NCT06870487），这项试验将在多种淋巴瘤或实体瘤患者中探索单药以及与PD-1抗体sasanlimab联用的疗效。这标志着在肿瘤治疗领域又迈出了重要一步。

近日，Elevation Oncology（以下简称“ELEV”）宣布终止其Claudin ...

在入组患者排除标准中，SYS6005将参加其他涉及靶向 ROR1 治疗，或者既往接受过含 MMAE 载荷ADC 治疗的研究的患者排除在外。 SYS6005也由此成为石药集团 ...

Disitamab Vedotin（DV，RC48，或 RC48-ADC）是一种新型人源化抗体 - 药物偶联物（ADC），它基于人表皮生长因子受体 2 抗体（anti-HER2，或曲妥珠单抗）与单甲基奥瑞他汀 E（MMAE）偶联而成。本研究旨在评估 RC48-ADC 联合程序性死亡蛋白 1（PD-1）抑制剂治疗局部晚期或转移 ...

Genmab has received approval from Japan's Ministry of Health, Labour and Welfare for its Tivdak to treat cervical cancer.

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with ...

antibody-drug conjugate (ADC), being developed for the treatment of triple-negative breast cancer (TNBC). INA-03 was constructed by conjugating an antimitotic payload (MMAE) to a humanized IgG4 ...

Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR ...

"With EO-1022, we are combining the most advanced site-specific conjugation technology platform with the clinically validated MMAE payload, which is widely used across ADC programs but has yet ...